Interestingly, Verachi et al. [101] discovered that the CXCR1/2 targeted allosteric inhibitor Reparixin also improves myelofibrosis progression and serves as the first-line clinical treatment for myelofibrosis patients. The gene discussed is CXCR1; the disease is myelofibrosis.